ANNEXON, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ANNEXON, INC. (ANNX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $4.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-12
- ANNEXON, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $4.81M, a 14.46% increase year-over-year.
- ANNEXON, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $4.16M, a 18.16% decline year-over-year.
- ANNEXON, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.83M, a 16.79% decline year-over-year.
- ANNEXON, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $4.21M, a 14.91% decline year-over-year.
- ANNEXON, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $16.42M, a 15.49% decline from fiscal 2024.
- ANNEXON, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $19.43M, a 6.87% increase from fiscal 2023.
- ANNEXON, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $18.18M, a 1.80% decline from fiscal 2022.
- ANNEXON, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $18.52M, a 13.86% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.81M 10-Q · filed 2026-08-12 | $8.97M derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $4.16M 10-Q · filed 2026-08-12 | |||
| 2025-12-31 | $16.42M 10-K · filed 2026-03-30 | |||
| 2025-09-30 | $3.83M 10-Q · filed 2025-11-10 | $8.04M derived: sum of 2 quarters · filed 2026-08-12 | $13.12M derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-06-30 | $4.21M 10-Q · filed 2026-08-12 | $9.28M derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $5.08M 10-Q · filed 2026-08-12 | |||
| 2024-12-31 | $19.43M 10-K · filed 2026-03-30 | |||
| 2024-09-30 | $4.61M 10-Q · filed 2025-11-10 | $9.55M derived: sum of 2 quarters · filed 2025-11-10 | $14.21M derived: sum of 3 quarters · filed 2025-11-10 | |
| 2024-06-30 | $4.94M 10-Q · filed 2025-11-10 | $9.60M derived: sum of 2 quarters · filed 2025-11-10 | ||
| 2024-03-31 | $4.66M 10-Q · filed 2025-11-10 | |||
| 2023-12-31 | $18.18M 10-K · filed 2025-03-03 | |||
| 2023-09-30 | $4.55M 10-Q · filed 2024-11-14 | $9.21M derived: sum of 2 quarters · filed 2024-11-14 | $13.82M derived: sum of 3 quarters · filed 2024-11-14 | |
| 2023-06-30 | $4.66M 10-Q · filed 2024-11-14 | $9.27M derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2023-03-31 | $4.61M 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | $18.52M 10-K · filed 2024-03-26 | |||
| 2022-09-30 | $4.91M 10-Q · filed 2023-11-13 | $9.43M derived: sum of 2 quarters · filed 2023-11-13 | $13.68M derived: sum of 3 quarters · filed 2023-11-13 | |
| 2022-06-30 | $4.52M 10-Q · filed 2023-11-13 | $8.77M derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2022-03-31 | $4.25M 10-Q · filed 2023-11-13 | |||
| 2021-12-31 | $16.26M 10-K · filed 2023-03-06 | |||
| 2021-09-30 | $4.43M 10-Q · filed 2022-11-03 | $8.95M derived: sum of 2 quarters · filed 2022-11-03 | $11.91M derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-06-30 | $4.52M 10-Q · filed 2022-11-03 | $7.48M derived: sum of 2 quarters · filed 2022-11-03 | ||
| 2021-03-31 | $2.96M 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | $4.89M 10-K · filed 2022-03-01 | |||
| 2020-09-30 | $1.47M 10-Q · filed 2021-11-09 | $2.23M derived: sum of 2 quarters · filed 2021-11-09 | $2.90M derived: sum of 3 quarters · filed 2021-11-09 | |
| 2020-06-30 | $763.00K 10-Q · filed 2021-11-09 | $1.43M derived: sum of 2 quarters · filed 2021-11-09 | ||
| 2020-03-31 | $663.00K 10-Q · filed 2021-11-09 | |||
| 2019-12-31 | $2.04M 10-K · filed 2021-03-25 | |||
| 2019-09-30 | $610.00K 10-Q · filed 2020-11-16 | $1.05M derived: sum of 2 quarters · filed 2020-11-16 | $1.51M derived: sum of 3 quarters · filed 2020-11-16 | |
| 2019-06-30 | $437.00K 10-Q · filed 2020-11-16 | $903.00K derived: sum of 2 quarters · filed 2020-11-16 | ||
| 2019-03-31 | $466.00K 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |